Opinion|Videos|June 11, 2024
Balancing Clinical and Economic Factors in Early Breast Cancer Treatment
The panelists discuss the clinical and economic factors that influence treatment decisions for early breast cancer (eBC), as well as the differences between eBC and metastatic breast cancer (mBC) in terms of adverse event management protocols and strategies for optimizing patient adherence.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What is the current standard of care for early breast cancer?
- What role do academic and community pharmacists have in the treatment plan?
- What are the clinical and economic considerations that go into deciding on a treatment option for eBC?
- What is the difference between eBC and mBC in terms of AE protocols and adherence optimization?
- Can any mBC practices apply to eBC?
Advertisement
Related to this article
Six-year NATALEE data show adjuvant ribociclib (Kisqali) plus endocrine therapy improves overall survival in high-risk HR+/HER2- early breast cancer, with pharmacist-led monitoring.
Pharmacists can help care for patients receiving breast cancer endocrine therapy by identifying fracture risk early and supporting appropriate bone-directed treatment throughout survivorship.
Tucatinib’s new HER2-positive breast cancer maintenance indication extends disease control while requiring close liver monitoring and pharmacist coordination of oral therapy with ongoing antibody treatment.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Cystatin C and the Future of Kidney Function Assessment
2
FDA Approves Talazoparib With Enzalutamide for HRR-Mutated Metastatic Prostate Cancer
3
Medicare GLP-1 Bridge Runs Outside Part D and Pharmacy Teams Need a Different Workflow
4
GLP-1 RAs, Finerenone, and CKD: Key Data From Kidney Week 2026
5